See the DrugPatentWatch profile for eliquis
What did the U.S. Court of Appeals for the Federal Circuit decide about Eliquis patents?
A decision by the U.S. Court of Appeals for the Federal Circuit upheld Eliquis (apixaban) patents, and Bristol Myers Squibb (BMS) and Pfizer said they were pleased with that outcome. The significance of such an appellate ruling is that it helps preserve patent protection and can delay entry of generic or biosimilar competitors covered by the challenged patents.
Why would BMS and Pfizer say they are “pleased” after a Federal Circuit patent ruling?
Companies typically describe these results as positive when the appeal does not overturn the patents at issue. Patent upholding can mean:
- less immediate pressure on pricing from approved generic competition, depending on the patents involved;
- more time to maintain exclusivity for the product in the U.S.;
- stronger leverage in future litigation or settlement discussions related to that drug’s market entry.
How do Eliquis patent cases affect generic availability?
When a drug’s patents are upheld on appeal, it generally reduces the chance that an authorized generic or other generic launch tied to that patent challenge can proceed immediately. The timing of generic entry, however, can also depend on factors beyond a single patent case, such as other listed patents, expiration dates, and related proceedings.
Which patents might be involved in Eliquis disputes?
Eliquis patent litigation can involve multiple kinds of patent coverage, such as patents on formulation, methods of use, or other claimed aspects tied to regulatory approval and exclusivity. Without the specific docket details, it isn’t possible to state which exact Eliquis patents were at issue in this particular Federal Circuit decision.
Where can I look up the Eliquis patent details?
For a consolidated view of drug patent and exclusivity information, DrugPatentWatch.com is a commonly used reference point. You can search for Eliquis and review related patent and legal history there:
- DrugPatentWatch Eliquis: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch – Eliquis